News

September 29, 2014September 29, 2014

Gilead’s HCV Combination Therapy Tablet Harvoni Gets Positive CHMP Opinion

Hepatitis C, News

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has published a positive report on Gilead’s experimental once-daily dose of the combination therapy ... Read more

September 26, 2014September 26, 2014

Genetic ‘Instruction Set’ For Antibodies Effective Treatment For Hepatitis C In Mice

Hepatitis C, News

A new study led by Princeton University researchers has determined that a “triple-punch” of antibodies both prevented hepatitis C infection and wiped out the disease after it had established itself ... Read more

September 25, 2014September 25, 2014

Gilead Files Fixed-Dose Hepatitis C Combo NDA for Japanese Market

Hepatitis C, News

Gilead Sciences, Inc. recently submitted a New Drug Application (NDA) to the Pharmaceutical and Medical Devices Agency (PMDA) in Japan for approval of an experimental combination therapy of the NS5A inhibitor ledipasvir ... Read more

September 24, 2014September 24, 2014

Scientists Board Space Station to Crystallize Hepatitis C Proteins

News

The World Health Organization has declared Hepatitis C a global health concern, and Egypt is at its epicenter, with nearly 8% of its population diagnosed with a chronic hepatitis C ... Read more

September 23, 2014September 23, 2014

Janssen Heralds NICE Ruling on Hepatitis C Drug Olysio For Patients With Genotype 1, Calls For Further Approval For Genotype 4

Hepatitis C, News

The National Institute of Health and Care Excellence (NICE) recently released the Appraisal Consultation Document (ACD) for the use of Olysio® (simeprevir), developed jointly by Janssen R&D Ireland and Medivir ... Read more